Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion

Technology appraisal guidance
Reference number: TA283
Published: 22 May 2013
Last updated: 20 May 2024

Macular oedema (retinal vein occlusion) - ranibizumab: Decision Support Unit (DSU) Report

Macular oedema (retinal vein occlusion) - ranibizumab: Decision Support Unit (DSU) Report

Macular oedema (retinal vein occlusion) - ranibizumab: Decision Support Unit (DSU) Report
11 April 2013
(1.43 Mb 6 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 10 April 2013